Like Bees to Honey: Cronos Group (TSX:CRON) Stock Attracts Huge Investments

Cronos Group Inc (TSX:CRON)(NASDAQ:CRON) acquired a hemp-based products platform in the United States.

| More on:

The Cronos Group (TSX:CRON)(NASDAQ:CRON) is set to soar on the Toronto Stock Exchange (TSX) next year.

On Thursday, the company announced the acquisition of four subsidiaries of Redwood Holding Group for US$300 million. On the news, trading volume increased by 60% above the average to over seven million shares. The increased trading activity continued throughout Friday.

In addition to the acquisition, the Cronos Group gained two new leaders from the agreement. Redwood founders Robert Rosenheck and Cindy Capobianco will continue to manage the acquired subsidiaries. The two cannabis entrepreneurs bring niche expertise in marijuana cultivation and distribution logistics.

Redwood Group

Founded in 2017 in Kansas, the Redwood Group is a private company based in the agricultural heartland of the United States. The location suggests that the company and its founders possess superior knowledge of the farming techniques required to cultivate quality cannabis.

Redwood Holding Group specializes in the development of hemp-derived cannabidiol (CBD) products. Online skincare and consumer product sales under the brand Lord Jones drive Redwood’s success in the adult-use market. Consumers are attracted to Lord Jones hemp oil, because it is certified, pure, and contains natural phytocannabinoids and terpenes.

The Redwood Group owns cannabis storage, cleaning, and processing facilities in the United States and Canada. Thus, the acquisition brings critical production equipment and processing capabilities to the Cronos Group. The additional production capacity will help Cronos meet growing demand in 2020 and beyond.

Cronos Group

The Cronos Group is a global cannabis research and development firm, boasting a supply and distribution chain spanning nearly all continents. Founded in 2012, the company produces cannabinoid oil under top brands such as Peace Naturals, Cove, and Spinach.

In the past year, Cronos increased net receivables by an impressive 75%. Moreover, the company also saw a surge in liabilities by almost five times last year’s expenses — the most significant increase in liabilities in the industry. The financials indicate that the company is making substantial investments in cash versus debt.

The low-debt financing strategy is good news for Cronos shareholders. The stock, which currently sells at just under $14 per share, has lagged behind competitors such as Canopy Growth.

Foolish takeaway

The Cronos Group is headed for a rise in market price in the next year. Speculative volatility has left many stocks over or undervalued on the stock exchange. Cronos is one of those undervalued stocks, and its reported financials look too clean to not attract new equity investment.

The company reported a levered free cash flow of $1.56 billion last year. Meanwhile, all major competitors, including Canopy Growth and Aurora Cannabis, posted negative free cash flows. Levered free cash flows are the remaining cash from operations after a company fulfills expense obligations.

Based on the financial data, the Cronos Group is a low-risk cannabis investment with fiscally responsible leadership. Moreover, Tax-Free Savings Account and Registered Retirement Savings Plan investors should feel comfortable with the reported return on equity. The Cronos Group has posted the highest return on investment in the industry at nearly 75%.

As the most undervalued cannabis stock on the TSX, Cronos is surely set to soar in the next year.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Debra Ray has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Should You Buy Canopy Growth Stock or Green Thumb Stock Today?

Let's dive into two cannabis giants, and which one may be the better pick for long-term investors.

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Could Aurora Cannabis Stock Finally Recover by Year-End?

Down 99% from all-time highs, Aurora Cannabis stock is focused on improving profit margins and expanding sales of its medical…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Are Pot Stocks About to Surge Again? 

With pot stocks making big moves of late, many investors are now asking whether the cannabis sector is worth investing…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Can Pot Stocks Aurora Cannabis and Canopy Growth Bounce Back in Q4?

Down over 99% from all-time highs, Canadian pot stocks such as Aurora Cannabis and Canopy Growth remain high-risk bets.

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »